NCT01379677View on ClinicalTrials.gov

Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head Comparison

PHASE3CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Coronary Artery Disease
Interventions
DRUG

Rubidium-82

Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use

DRUG

Sestamibi. reconstitution with sodium pertechnetate (99mTc)

Maximum dose allowed per injection: 1000 MBq Intravenous Use

Trial Locations (1)

NW1 2BU

University College Hospital London NHS Foundation Trust, London

Sponsors
All Listed Sponsors
lead

Advanced Accelerator Applications

INDUSTRY